SPL84 shows signs of improving lung function in CF patients
SPL84, an investigational inhalation therapy designed to treat cystic fibrosis (CF) caused by a specific mutation called 3849+10 kb C-to-T, was well tolerated in a Phase 2 clinical trial. Trial data also suggest that most CF patients treated with SPL84 experienced improvements in a measure of lung function, according…